FibroBiologics Reports Third Quarter 2026 Financial Results; Highlights Upcoming Catalysts
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
FibroBiologics (Nasdaq: FBLG) reported a third-quarter 2026 net loss of approximately $4.0 million while advancing its diabetic foot ulcer trial. Research and development expenses fell to approximately $2.1 million from $2.8 million a year earlier; general and administrative expenses declined to approximately $2.0 million from $2.2 million. Cash and cash equivalents totaled approximately $1.2 million at September 30, with approximately $1.0 million in subsequent cash infusions through November 16.
The company expects initial CYWC628 sentinel-cohort safety data in mid-December 2026 and interim efficacy data in February 2027, subject to trial progress and applicable regulatory approvals. Enrollment continued in Australia, supported by a third drug-product batch. Issued patents rose 38% to 170 from December 31, 2025. A $0.5 million private placement with the chief scientific officer closed in September.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Major pointApproximately $1.0 million in cash infusions followed September 30 through November 16, 2026. 15% of market cap
- Moderate pointResearch and development expenses decreased to approximately $2.1 million in Q3 2026 from approximately $2.8 million in Q3 2025.
- Moderate pointGeneral and administrative expenses decreased to approximately $2.0 million in Q3 2026 from approximately $2.2 million in Q3 2025.
- Moderate point$0.5 million private placement with the chief scientific officer closed in September 2026. 7.6% of market cap
- Moderate point. Forward-looking: it has not happened yet and may not happen.Initial CYWC628 safety data from the sentinel cohort are expected in mid-December 2026.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Interim CYWC628 efficacy data are anticipated in February 2027.
8 minor points
- Minor pointCYWC628 Phase 1/2 enrollment continued in Australia for diabetic foot ulcers.
- Minor pointThird CYWC628 batch passed required safety and quality testing and shipped to Australia in August 2026.
- Minor pointIssued patents increased 38% to 170 from 124 at December 31, 2025.
- Minor pointEuropean patent grants cover fibroblast delivery of tumor inhibitory agents and enhancement of fibroblast therapeutic activity.
- Minor pointU.S. patent application filed in October 2026 covers cell-based production of GLP-1 and other therapeutic peptides.
- Minor pointCYPS317 investigational new drug application updates continue based on FDA feedback for the psoriasis therapy.
- Minor point. Forward-looking: it has not happened yet and may not happen.CYMS101 application for permission to begin clinical testing is planned for 2027.
- Minor point. Forward-looking: it has not happened yet and may not happen.Degenerative disc disease application amendment is planned to replace single-cell fibroblasts with fibroblast-derived chondrocyte spheroids.
Negative
- Major pointNet loss totaled approximately $4.0 million for the three months ended September 30, 2026.
- Minor point. Forward-looking: it has not happened yet and may not happen.February 2027 interim efficacy reporting remains subject to trial progress and applicable regulatory approvals.
- Minor point. Forward-looking: it has not happened yet and may not happen.CYMS101 application submission depends on prior FDA clearance of the CYPS317 application.
Key Figures
- Research and development expenses
- approximately $2.1 million vs. approximately $2.8 million
- Three months ended September 30, 2026 vs. same period in 2025
- General and administrative expenses
- approximately $2.0 million vs. approximately $2.2 million
- Three months ended September 30, 2026 vs. same period in 2025
- Net loss
- approximately $4.0 million
- Three months ended September 30, 2026
- Cash and cash equivalents
- approximately $1.2 million
- At September 30, 2026
- Subsequent cash infusions
- approximately $1.0 million
- From September 30, 2026 to November 16, 2026
- Private placement
- $0.5 million
- Closed with the Company's Chief Scientific Officer in September 2026
- Initial safety data
- Mid-December 2026
- Phase 1/2 CYWC628 diabetic foot ulcer trial sentinel cohort; expected
- Interim efficacy data
- February 2027
- Phase 1/2 CYWC628 diabetic foot ulcer trial; anticipated, subject to trial progress and applicable regulatory approvals
Previous Earnings Reports
-
Completed initial CYWC628 manufacturing and site onboarding, advancing readiness for the now-enrolling trial.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
sentinel cohort medical
ind application regulatory
glp-1 medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Initial safety data from Phase 1/2 CYWC628 diabetic foot ulcer trial expected in Q4 2026; interim efficacy data expected in Q1 2027
- Issued patents increased
38% year to date to 170, with more than 325 issued and pending worldwide - Total operating expenses decreased
19% year over year
Third Quarter 2026 and Recent Highlights:
Clinical Updates:
- Continued enrolling patients in its Phase 1/2 clinical trial in
Australia evaluating the safety, tolerability and efficacy of CYWC628, an investigational fibroblast-based therapy for diabetic foot ulcers- Released the third batch of CYWC628 drug product following completion of required safety and quality testing and shipped it to
Australia in August 2026 to support continued enrollment.
- Released the third batch of CYWC628 drug product following completion of required safety and quality testing and shipped it to
Financing:
- Closed a
private placement with the Company's Chief Scientific Officer in September 2026.$0.5 million
Preclinical Progress:
- Presented preclinical data on fibroblast spheroid-derived chondrocyte spheroids for degenerative disc disease at the North American Spine Society (NASS) 2026 Annual Meeting in October 2026.
Intellectual Property:
- Increased its issued patent portfolio by
38% to 170 patents, up from 124 as of December 31, 2025, with more than 325 issued and pending patents worldwide. - Filed a
U.S . patent application in October 2026 for cell-based technology designed to produce GLP-1 and other therapeutic peptides inside the body. - Announced European patent grants covering fibroblast delivery of tumor inhibitory agents and methods of enhancing fibroblast therapeutic activity, further strengthening protection across its therapeutic platform.
Anticipated Near-Term Catalysts
Diabetic Foot Ulcers:
- Expects to report initial safety data from the Phase 1/2 trial's sentinel cohort in mid-December 2026.
- Anticipates reporting interim efficacy data in February 2027, subject to trial progress and applicable regulatory approvals.
Psoriasis:
- Continues updating its IND application for CYPS317, an investigational fibroblast spheroid therapy for psoriasis, based on feedback from the
U.S . Food and Drug Administration (FDA).
Multiple Sclerosis:
- Plans to submit an IND application for CYMS101 in 2027, following FDA clearance of the CYPS317 IND.
Degenerative Disc Disease:
- Plans to amend its existing IND to evaluate fibroblast-derived chondrocyte spheroids for the treatment of degenerative disc disease, replacing the previously proposed single-cell fibroblast approach.
"The third quarter was focused on continued execution. We continued enrollment in our Phase 1/2 diabetic foot ulcer trial, released our third batch of CYWC628 drug product and grew our issued patents by
Financial Highlights for the Quarter Ended September 30, 2026
- Research and development expenses were approximately
for the three months ended September 30, 2026, compared to approximately$2.1 million for the same period in 2025. The decrease was primarily due to decreased CRO costs of$2.8 million as clinical validation changed to manufacturing, and certain costs were capitalized to research and development supplies, decreased supplies expenses of$0.4 million , decreased sponsored research agreements of$0.2 million and increased payroll related costs associated with new personnel of approximately$0.3 million .$0.2 million
- General and administrative expenses were approximately
for the three months ended September 30, 2026 compared to approximately$2.0 million for the same period in 2025. The primary areas of net change are decreased personnel expenses of$2.2 million ; increased professional fees of$0.1 million for accounting, legal and marketing expenses; decreased facilities expenses of$0.1 million ; and increased listing expenses of$0.2 million .$0.1 million
- For the three months ended September 30, 2026, FibroBiologics reported a net loss of approximately
. The net loss for the three months ended September 30, 2026, was primarily due to research and development expenses and general and administrative expenses discussed above.$4.0 million
- Cash and cash equivalents totaled approximately
at September 30, 2026. Subsequent cash infusions from the balance sheet date to today totaled approximately$1.2 million .$1.0 million
Cautionary Statement Regarding Forward-Looking Statements
This communication contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include information concerning the expected timing and results of FibroBiologics' clinical trials, current and future clinical and preclinical development and regulatory plans, potential indications for product candidates, potential clinical benefits of fibroblasts and fibroblast-derived materials, the scope and strength of the Company's intellectual property portfolio, and the Company's liquidity, financing and capital needs. These statements are based on management's current expectations, estimates, projections and beliefs and assumptions about future events, and are not guarantees of future performance, conditions or results. Actual results could differ materially as a result of risks and uncertainties, including those described under "Risk Factors" and elsewhere in FibroBiologics' filings with the SEC, including Forms 10-K, 10-Q and 8-K and subsequent filings. Copies are available at www.sec.gov. Risks include, but are not limited to, (a) the Company's liquidity and ability to maintain sufficient capital resources; (b) the initiation, progress and results of research and development efforts, preclinical studies and clinical trials; (c) the unpredictable relationship between preclinical and clinical results; (d) the ability to prosecute patent applications; (e) the ability to manufacture product candidates; (f) the ability to conduct clinical trials; and (g) the ability to maintain compliance with Nasdaq rules. Forward-looking statements speak only as of the date they are made. Readers should not place undue reliance on these statements. Except as required by law, FibroBiologics assumes no obligation to update or revise forward-looking statements. FibroBiologics gives no assurance that it will achieve its expectations. [Legal review required before release.]
About the Technology
Fibroblasts are the most common cell type found in connective tissue and play a central role in tissue repair. They are abundant, can be isolated from donor tissue, and expand readily in culture, which makes them practical to manufacture as a cell therapy. FibroBiologics develops fibroblasts as cultured cells and as three-dimensional spheroids, together with fibroblast-derived materials such as conditioned media and extracellular vesicles. The company's patented approaches apply this platform to chronic diseases, with the goal of repairing tissue, modulating the immune system, and delivering therapeutic agents where they are needed.
For more information, please visit FibroBiologics' website, email FibroBiologics at info@fibrobiologics.com or follow FibroBiologics on LinkedIn, YouTube, Facebook or X.
About FibroBiologics
Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 325+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration. For more information, visit www.FibroBiologics.com.
General Inquiries:
info@fibrobiologics.com
Investor Relations:
Nic Johnson
Russo Partners
(212) 845-4242
fibrobiologicsIR@russopr.com
Media Contact:
Tierney Sovic
Russo Partners
(646) 942-5590
tierney.sovic@russopartnersllc.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/fibrobiologics-reports-third-quarter-2026-financial-results-highlights-upcoming-catalysts-302941034.html
SOURCE FibroBiologics, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
When will FibroBiologics report CYWC628 diabetic foot ulcer trial data?
FibroBiologics expects initial sentinel-cohort safety data in mid-December 2026 and anticipates interim efficacy data in February 2027. The efficacy reporting timeline is subject to trial progress and applicable regulatory approvals. The Phase 1/2 trial in Australia evaluates safety, tolerability and efficacy.
What were FibroBiologics' third-quarter 2026 loss and cash balance?
FibroBiologics reported a net loss of approximately $4.0 million for the three months ended September 30, 2026, and approximately $1.2 million in cash and cash equivalents at that date. Subsequent cash infusions through November 16, 2026, totaled approximately $1.0 million.
Why did FibroBiologics' research and development expenses decline in Q3 2026?
The decrease primarily reflected lower contract research organization costs, supplies expenses and sponsored research agreement expenses, partly offset by higher payroll-related costs for new personnel. Contract research organization costs fell as clinical validation changed to manufacturing, and certain costs were capitalized to research and development supplies.